Hebei Changshan Biochemical Pharmaceutical (SHE:300255) obtained drug registration from Moldova's drug regulatory authority for its heparin sodium injection, according to a Wednesday filing with the Shenzhen bourse.
The drug is used to prevent and treat thrombotic and embolic diseases, disseminated intravascular coagulation, and for anticoagulation during hemodialysis and various surgical procedures.
The registration is valid until July 2031.
Shares of the pharmaceutical company rose 1% Wednesday.